These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 2587023)
1. A comparative study concerning the treatment of active toxoplasmic retinochoroiditis with argon laser and medication (follow-up 2-9 years). Theodossiadis GP; Koutsandrea C; Tzonou A Ophthalmologica; 1989; 199(2-3):77-83. PubMed ID: 2587023 [TBL] [Abstract][Full Text] [Related]
5. [Interest in treatment with subconjunctival clindamycin in toxoplasmic retinochoroiditis]. Ben Zina Z; Abid D; Kharrat W; Chaker N; Aloulou K; Chaâbouni M Tunis Med; 2001 Mar; 79(3):157-60. PubMed ID: 11471444 [TBL] [Abstract][Full Text] [Related]
6. Trimethoprim-Sulfamethoxazole Versus Placebo in Reducing the Risk of Toxoplasmic Retinochoroiditis Recurrences: A Three-Year Follow-up. Fernandes Felix JP; Cavalcanti Lira RP; Cosimo AB; Cardeal da Costa RL; Nascimento MA; Leite Arieta CE Am J Ophthalmol; 2016 Oct; 170():176-182. PubMed ID: 27521607 [TBL] [Abstract][Full Text] [Related]
7. Toxoplasmic retinochoroiditis: resolution without treatment of the perilesional satellite dark dots seen by indocyanine green angiography. Guex-Crosier Y; Auer C; Bernasconi O; Herbort CP Graefes Arch Clin Exp Ophthalmol; 1998 Jun; 236(6):476-8. PubMed ID: 9646094 [TBL] [Abstract][Full Text] [Related]
8. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Silveira C; Belfort R; Muccioli C; Holland GN; Victora CG; Horta BL; Yu F; Nussenblatt RB Am J Ophthalmol; 2002 Jul; 134(1):41-6. PubMed ID: 12095806 [TBL] [Abstract][Full Text] [Related]
10. [Efficacy of specific chemotherapy in the prevention of recurrences of toxoplasmic chorioretinitis during the 4 years following the treatment]. Timsit JC; Bloch-Michel E J Fr Ophtalmol; 1987; 10(1):15-23. PubMed ID: 3598056 [TBL] [Abstract][Full Text] [Related]
11. Photocoagulation of active toxoplasmic retinochoroiditis. Ghartey KN; Brockhurst RJ Am J Ophthalmol; 1980 Jun; 89(6):858-64. PubMed ID: 6966892 [TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to toxoplasmic retinochoroiditis: a case series. Kianersi F; Naderi Beni A; Naderi Beni Z; Ghanbari H Semin Ophthalmol; 2015 May; 30(3):181-7. PubMed ID: 24175641 [TBL] [Abstract][Full Text] [Related]
14. Temporal changes in a giant macular hole formed secondary to toxoplasmic retinochoroiditis. Tanaka R; Obata R; Sawamura H; Ohtomo K; Kaburaki T Can J Ophthalmol; 2014 Oct; 49(5):e115-8. PubMed ID: 25284113 [No Abstract] [Full Text] [Related]
15. Toxoplasmic retinochoroiditis: The influence of age, number of retinochoroidal lesions and genetic polymorphism for IFN-γ +874 T/A as risk factors for recurrence in a survival analysis. Aleixo ALQDC; Vasconcelos C de Oliveira R; Cavalcanti Albuquerque M; Biancardi AL; Land Curi AL; Israel Benchimol E; Reis Amendoeira MR PLoS One; 2019; 14(2):e0211627. PubMed ID: 30753197 [TBL] [Abstract][Full Text] [Related]
17. Verteporfin photodynamic therapy for choroidal neovascularization associated with toxoplasmic retinochoroiditis. Mauget-Faÿsse M; Mimoun G; Ruiz-Moreno JM; Quaranta-El Maftouhi M; De Laey JJ; Postelmans L; Soubrane G; Defauchy M; Leys A Retina; 2006 Apr; 26(4):396-403. PubMed ID: 16603957 [TBL] [Abstract][Full Text] [Related]
18. Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months. Lasave AF; Díaz-Llopis M; Muccioli C; Belfort R; Arevalo JF Ophthalmology; 2010 Sep; 117(9):1831-8. PubMed ID: 20471684 [TBL] [Abstract][Full Text] [Related]
19. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Soheilian M; Sadoughi MM; Ghajarnia M; Dehghan MH; Yazdani S; Behboudi H; Anisian A; Peyman GA Ophthalmology; 2005 Nov; 112(11):1876-82. PubMed ID: 16171866 [TBL] [Abstract][Full Text] [Related]